THE popular traditional Chinese medicine (TCM) Lianhua Qingwen capsule is officially launched in the Philippine market through the efforts of Yiling Pharmaceutical and its exclusive Philippine distributor, Philippine Archipelago International Trading Corporation. Making it the first TCM to be registered as a traditionally used herbal product in the Philippines.
During the product launch, Olivia Limpe-Aw, the president of Philippine Archipelago International Trading Corporation stated that “The Covid-19 Pandemic has brought to the fore the importance and significance of TCM and the significant role of Lianhua Qingwen in particular in the prevention, treatment and control of this global epidemic.”
Lianhua Qingwen Capsule has been part of China’s standard therapy for mild and moderate coronavirus patients. It’s listed as a recommended medicine in the Diagnosis and Treatment Scheme of Novel Coronavirus Pneumonia (Versions #4-#8), issued officially by Chinese authorities.
The results of a prospective, randomized, controlled, and multi-center clinical study on treating Covid-19 with Lianhua Qingwen Capsules, which Chinese Academicians Zhong Nanshan, Li Lanjuan, and Zhang Boli and other experts worked on together with over 20 hospitals, were published in Phytomedicine, the journal with a high impact factor in the field of international herbal medicine. It’s found in the study in terms of clinical use that Lianhua Qingwen proved to be both safe and effective in treating Covid-19.
“It is our sincere hope that Lianhua Qingwen’s entrance into the Philippine market will contribute to the fight against the spread of Covid-19 in this country,” Yunling Zhang, VP of the drug’s manufacturer, Yiling Pharmaceutical, said during the launch. “It helped millions of patients during the coronavirus outbreak in both China and other countries.”
It is currently available in selected Mercury Drug and Southstar Drug and soon to be available in Watsons stores.